M&A & Funding

W.L. Gore completed its acquisition of Conformal Medical in February 2026, adding the investigational CLAAS AcuForm left atrial appendage occlusion system to its cardiovascular portfolio. Covers foam-based LAAO technology designed to conform to variable anatomies, the $1.2B LAAO device market dominated by Boston Scientific's Watchman and Abbott's Amulet, the CONFORM pivotal trial, and how a rare strategic acquisition by the privately held materials science giant reshapes competitive dynamics in structural heart.

Medtronic completed its acquisition of CathWorks for $585M in April 2026, adding the AI-powered FFRangio system for non-invasive coronary physiology assessment, and signed a definitive agreement to acquire Scientia Vascular for $550M in March 2026 for its microfabricated neurovascular guidewires and catheters. Covers how the AI-driven FFRangio system derives fractional flow reserve from routine angiograms, Scientia's nitinol microfabrication technology for stroke intervention, and Medtronic's post-MiniMed acquisition strategy focused on high-growth cardiovascular and neuroscience tuck-in deals.

Roche entered a definitive agreement to acquire PathAI on May 7, 2026, for $750M upfront plus up to $300M in milestone payments, adding the AISight digital pathology platform and AI-based biomarker algorithms to its diagnostics division. Covers PathAI's technology for cancer screening and companion diagnostic development, the $1.1B+ AI pathology market, regulatory considerations for AI/ML-based SaMD, and implications for precision oncology and IVD regulatory strategy.

CareDx agreed to acquire Naveris for up to $260M on April 28, 2026, marking its strategic expansion from transplant diagnostics into HPV-driven cancer surveillance. Covers NavDx liquid biopsy technology, TTMV DNA biomarker science, deal structure ($160M upfront + $100M milestones), CareDx's divestiture of Lab Products, and the $4.5B molecular residual disease monitoring market.

Johnson & Johnson entered a definitive agreement to acquire Atraverse Medical on April 24, 2026, adding the FDA-cleared HOTWIRE Transseptal Access System to its cardiac ablation portfolio. Covers RF-guidewire technology for left-heart access, the Atraverse founding team behind Farapulse (Boston Scientific), J&J's electrophysiology strategy including Shockwave and Varipulse, and the competitive landscape in the $10B+ cardiac rhythm management market.

Stryker completed its acquisition of Amplitude Vascular Systems on May 7, 2026, adding next-generation intravascular lithotripsy (IVL) technology to its peripheral vascular portfolio. Covers the CO2-generated pressure wave platform, why IVL matters for calcified PAD treatment, competitive dynamics with J&J/Shockwave, regulatory pathway, and implications for the $4B+ peripheral vascular device market.

In-depth analysis of Bayer's acquisition of Perfuse Therapeutics for up to $2.45 billion, marking its return to M&A after a 5-year drought. Covers the PER-001 intravitreal implant for glaucoma and diabetic retinopathy, deal structure, endothelin receptor antagonism mechanism, the growing drug-device combination product market, and what it means for ophthalmic medtech manufacturers and investors.

Sun Pharmaceutical Industries agreed to acquire Organon & Co. for $11.75 billion in the largest pharmaceutical deal of 2026 and India's largest overseas pharma acquisition. Covers deal structure, Organon's portfolio of women's health products (Nexplanon, NuvaRing) and biosimilars (Hadlima, Renflexis), the drug-device combination products involved, regulatory considerations for combination products, and what the deal means for the women's health and biosimilar device landscape.

In-depth analysis of Danaher's $9.9 billion acquisition of Masimo, the largest medtech deal of 2026. Covers deal structure, strategic rationale, regulatory and antitrust considerations, competitive landscape impact on patient monitoring, and what it means for device manufacturers, hospitals, and investors.

The medical device CDMO market is projected to grow from $134.65 billion in 2025 to $354.60 billion by 2033 at 13.12% CAGR. This guide covers market size, growth drivers, key players (Jabil, Integer, Flex, Plexus), M&A trends, and how to choose the right contract manufacturing partner.

A data-driven analysis of the AI medical device investment boom — covering the Medtronic/CathWorks deal, Zimmer Biomet/Monogram acquisition, HistoSonics' $2.25B valuation, record FDA AI clearances, and how AI now drives 55% of all health tech funding in 2025-2026.

Comprehensive analysis of the Middle East & North Africa medical device market — $24.6B in 2025 growing to $35B by 2032 at 5.1% CAGR. Saudi Arabia's $35.5B Global Health Exhibition deals, 400 GCC healthcare transactions (2021–2025), UAE $3.18B market, Egypt $4.37B, digital health at 19.6% CAGR, and smart devices growing at 10.16% CAGR.

A data-driven tracker of every major medtech M&A deal in 2025 and 2026 — from Abbott's $21B Exact Sciences acquisition to Boston Scientific's $14.5B Penumbra buy — with deal values, strategic rationale, and industry trends.

A data-driven analysis of why cardiovascular devices dominate medtech M&A — covering the Stryker/Inari, Boston Scientific/Penumbra, and Medtronic/CathWorks deals, the PFA revolution, structural heart innovation, and the forces driving CV dealmaking in 2025-2026.

An in-depth analysis of how the Federal Trade Commission is reshaping medtech dealmaking — from blocking the Edwards/JenaValve TAVR deal to the GTCR/Surmodics outcome, HSR filing changes, and the rise of state-level mini-HSR laws.

A comprehensive guide to medical device company valuation in 2025-2026 — covering EBITDA and revenue multiples by subsector, valuation methods for pre-revenue and commercial-stage companies, deal structures including earn-outs and CVRs, and the due diligence process.

A practical guide to raising venture capital for medical device startups in 2026 — covering typical raise amounts by stage, what investors evaluate, hot subsectors, the VC ecosystem, and how to position for a successful fundraise.

A comprehensive analysis of the wave of medtech divestitures and spinoffs reshaping the industry — from BD's $17.5B Waters deal to J&J's DePuy Synthes separation, Siemens Healthineers deconsolidation, and Medtronic's MiniMed IPO.

A comprehensive analysis of the medtech and healthcare IPO landscape in 2026 — from Medline's record $6.3B listing and Medtronic's MiniMed Diabetes spinoff IPO to digital health debuts, SPAC resurgence, and what's in the pipeline.

A deep dive into private equity's growing role in medtech — from Blackstone and TPG's landmark $18.3B Hologic take-private to buy-and-build platforms, CDMO acquisitions, the record Medline IPO exit, and PE dry powder deployment strategies.